Lupin has announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin's Silodosin Capsules 4mg and 8mg; is the generic equivalent of Allergan's Rapaflo®. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Rapaflo® had annua l sales of $198.5 million in the US (IQVIA MAT September 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.888.05 as compared to the previous close of Rs. 898.25. The total number of shares traded during the day was 48447 in over 1296 trades.
The stock hit an intraday high of Rs. 905.9 and intraday low of 880. The net turnover during the day was Rs. 43192709.